Liquid Biopsy & MRD

BioMarin Acquires Amicus Therapeutics in $4.8B Rare Disease Consolidation

George Padron
Specialty Medicine, Healthcare Headlines, Liquid Biopsy & MRD | Dec 22, 2025
BioMarin's $4.8B Amicus acquisition adds Galafold for Fabry disease and Pompe treatment, generating $600M in revenue. The deal expands the rare disease portfolio to 10 products.

Nonprofit Partnership Establishes Novel Access Model for Ultra-Rare Disease Gene Therapy

George Padron
Precision Medicine, Policy & Legislation, Liquid Biopsy & MRD | Dec 15, 2025
Nonprofits partner to commercialize the first Wiskott-Aldrich gene therapy in US, creating a novel ultra-rare disease access model post-FDA approval.

Employers Assert Greater Control Over Pharmacy Benefits Amid Rising Treatment Costs

George Padron
Prior Authorization & Appeals, Cost-Effective Analysis, Precision Medicine, Healthcare Headlines, Healthcare Systems & Business, Transplant Diagnostics, Liquid Biopsy & MRD | Oct 10, 2025
Survey finds employers asserting control over pharmacy benefits with just 41% accepting standard formularies and 69% using data to hold vendors accountable.

State Medicaid Program Weighs Coverage Pause for Gene Therapy Amid Safety Concerns

Sonia Reyes
Prior Authorization & Appeals, Healthcare Headlines, Transplant Diagnostics, Liquid Biopsy & MRD | Oct 9, 2025
New York's Drug Utilization Review Board recommends pausing Medicaid coverage of Sarepta's Elevidys gene therapy due to safety concerns and a $45M annual cost.

Payer Challenges Mount as Gene Therapy Companies Retreat

George Padron
Medicare/Medicaid Updates, Precision Medicine, Healthcare Headlines, Transplant Diagnostics, Liquid Biopsy & MRD | Oct 9, 2025
Gene therapy manufacturers step back from blood disorder treatments despite regulatory approval, facing cost barriers and competition from improved transplant methods.

Immune System Breakthrough Earns Nobel Recognition With Treatment Implications

Sonia Reyes
AI & Critical Decision Support, Transplant Diagnostics, Liquid Biopsy & MRD | Oct 5, 2025
Three scientists win Nobel Prize for discovering regulatory T cells and genetic mechanisms that prevent autoimmune disease and enable new cancer treatments.

Liquid Biopsy & MRD

BioMarin Acquires Amicus Therapeutics in $4.8B Rare Disease Consolidation

Nonprofit Partnership Establishes Novel Access Model for Ultra-Rare Disease Gene Therapy

Employers Assert Greater Control Over Pharmacy Benefits Amid Rising Treatment Costs

State Medicaid Program Weighs Coverage Pause for Gene Therapy Amid Safety Concerns

Payer Challenges Mount as Gene Therapy Companies Retreat

Immune System Breakthrough Earns Nobel Recognition With Treatment Implications

Latest News

Dr. Eleonora Teplinsky on ASCO 2026 GLP-1 and Breast Cancer Prevention Data

Study Finds Parkinson's Genetic Yield Varies from 0.4% to 10.7% Based on Ancestry

Merck's Oral PCSK9 Inhibitor Approval Undercuts Injectables

Air Quality Alerts Blanket the Northeast as Canadian Smoke Pushes the AQI Into the Unhealthy Band

Care Partners Often Overlooked Patient Portal Users

Who We Are

Connect